High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core‐binding factor
Authors:
- Takahiro AokiTATakahiro Aoki
- Norio ShibaNSNorio Shiba
- Shinichi TsujimotoSTShinichi Tsujimoto
- Genki YamatoGYGenki Yamato
- Yusuke HaraYHYusuke Hara
- Shota KatoSKShota Kato
- Kenichi YoshidaKYKenichi Yoshida
- Seishi OgawaSOSeishi Ogawa
- Shotaro IwamotoSIShotaro Iwamoto
- Tomohiko TakiTTTomohiko Taki
- Akira ShimadaASAkira Shimada
- 6 December 2023
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (2) , e30803
Abstract
CD25 is an aberrant marker expressed on the leukemic stem cell (LSC) surface and an immunotherapy target in acute myeloid leukemia (AML). However, the clinical prevalence and significance of CD25 expression in pediatric AML are unknown. High IL2RA/CD25 expression in pediatric AML showed a stem cell‐like phenotype, and elevated CD25 expression was associated with lower overall survival (p < .001) and event‐free survival (p < .001) in the Japanese Pediatric Leukemia/Lymphoma Study Group AML‐05 study. This finding was reproduced in AML without a core‐binding factor in the Children's Oncology Group study cohort. High CD25 expression has prognostic significance in pediatric AML.Keywords
This publication has 21 references indexed in Scilit:
- High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3‐ITD,KMT2A‐PTD, and NUP98‐NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML‐05 trialBritish Journal of Haematology, 2015
- NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG reportBlood, 2014
- Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531Journal of Clinical Oncology, 2014
- Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in childrenLeukemia, 2013
- Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML)British Journal of Haematology, 2012
- CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900Blood, 2012
- AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemiaCancer, 2011
- Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem CellsScience Translational Medicine, 2010
- Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AMLEuropean Journal of Cancer, 2009
- Clinical implications of FLT3 mutations in pediatric AMLBlood, 2006